Skip to main content

Advertisement

Table 2 Patient disposition (randomised set)

From: A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

All patients   800:640 (N = 148) 800:960 (N = 151) 800:1440 (N = 149) Total (N = 448)
Treated n (%) 143 (96.6) 148 (98.0) 146 (98.0) 437 (97.5)
Completed n (%) 57 (38.5) 56 (37.1) 65 (43.6) 178 (39.7)
Premature study discontinuation n (%) 91 (61.5) 95 (62.9) 84 (56.4) 270 (60.3)
Primary reason for premature study discontinuation
 Criteria met for established anti-malarial treatment n (%) 68 (45.9) 79 (52.3) 64 (43.0) 211 (47.1)
 Study drug discontinued n (%) 0 4 (2.6) 3 (2.0) 7 (1.6)
 Withdrawal of consent n (%) 9 (6.1) 3 (2.0) 7 (4.7) 19 (4.2)
 Investigator’s opinion n (%) 1 (0.7) 1 (0.7) 0 2 (0.4)
 Patient non-compliant n (%) 0 1 (0.7) 0 1 (0.2)
 Adverse event n (%) 0 0 1 (0.7) 1 (0.2)
 Lost to follow-up n (%) 5 (3.4) 3 (2.0) 3 (2.0) 11 (2.5)
 Other n (%) 8 (5.4) 4 (2.6) 6 (4.0) 18 (4.0)
  1. n number of patients in each category/%)